Ondosis

About Ondosis

OnDosis is a Swedish life science startup that is revolutionizing the way medications are delivered and managed. The company focuses on creating intelligent solutions that combine high-quality pharmaceuticals with advanced digital technology. Their primary product is a handheld device that integrates medicine with intelligent dosing and digital support, making it easier and more effective for patients to follow their prescribed therapies.

OnDosis serves a diverse range of clients, including patients with chronic conditions such as ADHD, rare diseases, cancer, epilepsy, and those requiring immunosuppression for organ transplants. By targeting these high-need areas, the company aims to alleviate significant burdens on both patients and healthcare providers.

Operating in the healthcare and pharmaceutical market, OnDosis leverages its proprietary technology to offer flexible and individualized dosing of oral medications. This approach not only enhances disease management but also improves patient adherence to their medication regimens, providing greater convenience and reassurance.

The business model of OnDosis revolves around the development and sale of their intelligent dosing devices and the associated pharmaceuticals. They generate revenue through the sale of these devices and potentially through partnerships with pharmaceutical companies and healthcare providers who see the value in their innovative approach.

OnDosis is backed by a strong leadership team with extensive experience in healthcare, pharmaceuticals, and business development. This includes board members with backgrounds in major companies like AstraZeneca and Radforsk, as well as experts in strategic consulting and private equity investments in the healthcare sector.

In summary, OnDosis is dedicated to transforming medication delivery through intelligent, user-friendly solutions that cater to the specific needs of patients with chronic and complex conditions.